
Opinion|Videos|August 8, 2024
Patient with Unresectable Stage IIIB EGFR-Mutant NSCLC with N2 Bulky Disease
The panel looks at a second patient case study.
Advertisement
Episodes in this series

Advertisement
Related to this article

Thomas Powles, MBBS, MRCP, MD, discusses LITESPARK-022 QOL findings and patient selection for adjuvant belzutifan plus pembrolizumab in RCC.

Gov. Hochul unveils a cell and gene therapy fellowship between Roswell Park and San Juan City Hospital to train Puerto Rico physicians in advanced cancer care.

Retrospective data tie longer survival with niraparib maintenance to homologous recombination deficiency after complete primary debulking.

A meta-analysis of 4 sonrotoclax cohorts showed consistent response activity and low tumor lysis rates in heavily pretreated mantle cell lymphoma.

Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.

Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.

Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.
Advertisement
Advertisement
Trending on OncLive
1
Genomic Testing, Toxicity, and Sequencing Shape Treatment Decisions in Advanced Prostate Cancer
2
Dr Natsuhara on Treatment Advances and Research Considerations in TNBC
3
Dr Nunnery on Chemo De-Escalation, Ovarian Function Suppression, and Toxicity Management in Breast Cancer
4
NATALEE 6-Year OS Data and Novel ADCs in Breast Cancer Take Center Stage at ESMO 2026
5

